Literature DB >> 27622987

Visible light-induced solar urticaria is improved by omalizumab.

Marie Moncourier1, Safaë Assikar1, Ioana Matei1, Nicole Souyri1, Marion Couture1, Emilie Rigot1, Stéphanie Delauménie1, Christophe Bédane1.   

Abstract

Entities:  

Keywords:  omalizumab; solar urticaria; visible light

Year:  2016        PMID: 27622987     DOI: 10.1111/phpp.12271

Source DB:  PubMed          Journal:  Photodermatol Photoimmunol Photomed        ISSN: 0905-4383            Impact factor:   3.135


× No keyword cloud information.
  1 in total

1.  Long term treatment with omalizumab in adolescent with refractory solar urticaria.

Authors:  Mauro Iannelli; Stefano Passanisi; Giuseppe Crisafulli; Stefania Arasi; Lucia Caminiti; Giuseppina Zirilli; Giovanni B Pajno
Journal:  Ital J Pediatr       Date:  2021-09-28       Impact factor: 2.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.